BSH 2017 | Do we need to stratify follicular lymphoma (FL) patients for treatment?
Jessica Okosun, MA, MB, BChir, PhD, MRCP, FRCPath of Barts Cancer Institute, London, UK, discusses the follicular lymphoma (FL) treatment landscape at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. She explains the standard of care in the UK, and highlights that despite patient heterogeneity, all patients receive the same chemoimmunotherapy. Dr Okosun argues that the underlying biological heterogeneity means patients should be stratified rather than using the same treatment for all patients.
Get great new content delivered to your inboxSign up